Search research articles
Contact Us
Filters
Showing results (81-90 of 93) with videos related to
Page
of 10
Sort By:
Cancer Chemotherapy and Pharmacology
|
April 17, 2008
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine
Smitha S Krishnamurthi, Joanna M Brell, Charles L Hoppel, et al.
Hematological Oncology
|
March 2, 2011
Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning
Mehdi Hamadani, Michael Craig, Gary S Phillips, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2008
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group
Ramesh K Ramanathan, Merrill J Egorin, Chris H M Takimoto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 19, 2007
Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function
Chris H Takimoto, Martin A Graham, Graham Lockwood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 16, 2003
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
Chris H Takimoto, Scot C Remick, Sunil Sharma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 3, 2007
Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin
Beth Overmoyer, Pingfu Fu, Charles Hoppel, et al.
Cancer Chemotherapy and Pharmacology
|
April 12, 2011
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
Ticiana B Leal, Scot C Remick, Chris H Takimoto, et al.
Blood
|
December 22, 2009
Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma
Joseph A Sparano, Jeannette Y Lee, Lawrence D Kaplan, et al.
Learning Health Systems
|
July 22, 2024
Seeking American Society of Clinical Oncology-Quality Oncology Practice Initiative (ASCO-QOPI) certification in a northern New England rural health system and cancer care network
Hilary M Perrey, Evelyn Taylor, Brett F Cropp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2009
Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa
Walter O Mwanda, Jackson Orem, Pingfu Fu, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 93) with videos related to
Sort By:
Page
of 10
Cancer Chemotherapy and Pharmacology
|
April 17, 2008
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine
Smitha S Krishnamurthi, Joanna M Brell, Charles L Hoppel, et al.
Hematological Oncology
|
March 2, 2011
Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning
Mehdi Hamadani, Michael Craig, Gary S Phillips, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2008
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group
Ramesh K Ramanathan, Merrill J Egorin, Chris H M Takimoto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 19, 2007
Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function
Chris H Takimoto, Martin A Graham, Graham Lockwood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 16, 2003
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
Chris H Takimoto, Scot C Remick, Sunil Sharma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 3, 2007
Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin
Beth Overmoyer, Pingfu Fu, Charles Hoppel, et al.
Cancer Chemotherapy and Pharmacology
|
April 12, 2011
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
Ticiana B Leal, Scot C Remick, Chris H Takimoto, et al.
Blood
|
December 22, 2009
Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma
Joseph A Sparano, Jeannette Y Lee, Lawrence D Kaplan, et al.
Learning Health Systems
|
July 22, 2024
Seeking American Society of Clinical Oncology-Quality Oncology Practice Initiative (ASCO-QOPI) certification in a northern New England rural health system and cancer care network
Hilary M Perrey, Evelyn Taylor, Brett F Cropp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2009
Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa
Walter O Mwanda, Jackson Orem, Pingfu Fu, et al.
Page
of 10